NDA vs FDA Approval: What Each Milestone Means

An NDA starts a decision process

A New Drug Application is the sponsor's formal request for FDA to consider approving a new drug for U.S. marketing. It gives FDA the evidence and product information needed to evaluate the proposed use.

The application is not the decision. Saying that an NDA was submitted describes a request made by the sponsor, not an FDA approval.

Submitted, filed, under review, and approved mean different things

After FDA receives an NDA, the agency has 60 days to decide whether to file the application for review. Filing means the application can move into full review. It still does not mean FDA has approved the drug.

A filing decision is an application-completeness step. It does not mean FDA agrees with the sponsor's evidence or proposed labeling. The review team still evaluates the evidence, proposed labeling, and manufacturing controls before the agency acts.

During review, FDA evaluates the application. The process ends with an agency action, which may be an approval or a complete response letter when the application is not ready for approval.

FDA reviews more than clinical results

FDA describes an NDA as a record of the drug's evidence and product information. Review covers evidence for the proposed use, proposed labeling, and the controls used to manufacture the product.

A positive trial headline addresses only part of that record. It does not by itself establish that an NDA was submitted, filed, or approved.

Verify the final status in FDA records

An NDA number identifies an application, but the number alone does not state the current review outcome. Product status should be confirmed with an FDA approval record or approval letter.

Drugs@FDA provides information about approved products and can include labels, approval letters, and review materials. The separate GLP-1 approval-check guide explains how to keep product identity, dosage form, and approved use aligned during that lookup.

Keep process terms separate from product-specific claims

A general FDA-process page cannot establish whether a particular GLP-1 candidate has submitted an application or received a decision. Those are current, product-specific claims that require current product-specific evidence.

For that reason, this page does not state or predict a retatrutide NDA date or approval date. The named-reviewed retatrutide FDA status page remains the source for that separate intent.

FDA application milestones in plain language

NDA vs FDA Approval: What Each Milestone Means questions